Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics Stock Forecast

Stock Price Forecast

The 16 analysts that cover Nurix Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $30.44, which forecasts a 139.12% increase in the stock price over the next year. The lowest target is $16 and the highest is $41.

Price Target: $30.44 (+139.12%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$16	$30.44	$31	$41
Change	+25.69%	+139.12%	+143.52%	+222.07%

* Price targets were last updated on Apr 29, 2025.

Analyst Ratings

The average analyst rating for Nurix Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25	Apr '25	May '25	Jun '25
Strong Buy	7	7	7	7	7	7
Buy	9	9	8	8	8	7
Hold	1	1	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	17	17	17	17	17	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gil Blum Needham	Needham	Strong Buy Reiterates $27	Strong Buy	Reiterates	$27	+112.10%	Apr 29, 2025
Derek Archila Wells Fargo	Wells Fargo	Buy Maintains $32 → $25	Buy	Maintains	$32 → $25	+96.39%	Apr 9, 2025
Stephen Willey Stifel	Stifel	Strong Buy Maintains $36 → $35	Strong Buy	Maintains	$36 → $35	+174.94%	Apr 9, 2025
Gil Blum Needham	Needham	Strong Buy Maintains $28 → $27	Strong Buy	Maintains	$28 → $27	+112.10%	Apr 9, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $36	Strong Buy	Reiterates	$36	+182.80%	Apr 2, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

63.65M

Increased by 16.69%

from 54.55M

Revenue Next Year

59.69M

Decreased by -6.23%

from 63.65M

EPS This Year

-3.08

from -2.88

EPS Next Year

-3.31

from -3.08

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Nov 30, 2020	Nov 30, 2021	Nov 30, 2022	Nov 30, 2023	Nov 30, 2024	Nov 30, 2025	Nov 30, 2026	Nov 30, 2027
Revenue	17.82M	29.75M	38.63M	76.99M	54.55M	63.65M	59.69M	83.36M
Revenue Growth	-42.73%	66.95%	29.84%	99.31%	-29.15%	16.69%	-6.23%	39.67%
EPS	-2.76	-2.73	-3.71	-2.65	-2.88	-3.08	-3.31	-3.20
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	20	19	15

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	93.7M	99.8M	214.5M
Avg	63.7M	59.7M	83.4M
Low	18.1M	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	71.8%	56.7%	259.4%
Avg	16.7%	-6.2%	39.7%
Low	-66.8%	-	-

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-2.14	-1.70	-1.30
Avg	-3.08	-3.31	-3.20
Low	-3.49	-4.51	-4.07

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.